1. Home
  2. News
  3. Arovella Therapeutics Limited
  4. CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

CLDN18.2 CAR-T cells eliminate pancreatic cancer cells

Oct 2, 2025 at 12:08 AM EDT · Issued by Arovella Therapeutics Limited

Filed with ASX · Oct 2, 2025 at 12:08 AM EDT · 4 pages · English

On 6ix: 6ix.com/news/cldn18.2-car-t-cells-eliminate-pancreatic-cancer-cells

Arovella Therapeutics Limited on 6ix

Earlier from Arovella Therapeutics

  • Arovella receives R&D tax rebate of $3.21 millionSep 22, 2025
  • S&P DJI Announces September 2025 Quarterly RebalanceSep 5, 2025
  • Appendix 4E and Annual ReportAug 21, 2025
  • S&P DJI Announces March 2025 Quarterly RebalanceMar 7, 2025
  • Research Agreement with University of North CarolinaMar 3, 2025

Later from Arovella Therapeutics

  • Positive FDA Type D Meeting OutcomeOct 27, 2025
  • Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive DirectorNov 11, 2025
  • Quarterly Activities/Appendix 4C Cash Flow ReportJan 22
  • ALA's IND for ALA-101 accepted by the U.S.FDAJan 28
  • Half Year Report and Appendix 4DFeb 19
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer